Dr. José María Molero García: Most Seasonal Respiratory Infections Are Viral, Antibiotics Ineffective, per Saber Vivir Interview

Sore throats, coughs and colds will fill family doctor offices across Spain and Europe this winter, and most patients will not need the antibiotic they expect: roughly four in five of these seasonal respiratory infections are viral, against which antibiotics do nothing, while drug-resistant bacteria already cause more than 35,000 deaths in the European Union each year, Saber Vivir reported in its interview published on Tuesday with Dr. José María Molero García.

Molero García, a member of the infectious diseases working group of the Spanish Society of Family and Community Medicine (semFYC), argues that the measure of a good consultation is not the colour of the prescription pad.

“Debemos explicar a los pacientes que no prescribir un antibiótico no significa dejarlos sin tratamiento. Significa ofrecer la atención más adecuada,” he told Saber Vivir, translated: “We must explain to patients that not prescribing an antibiotic does not mean leaving them without treatment. It means offering the most appropriate care.”

The clinical arithmetic behind the warning is stark. Antibiotics act only on bacteria, not viruses, so when they are taken for a viral cold or flu they do not cure anything. What they do instead is disturb the patient’s microbiota — the community of bacteria living in the gut and elsewhere — and apply selection pressure that lets resistant strains survive and multiply.

Antibiotics do not treat viral infections

  • Antibiotics kill bacteria, not viruses. A cold, flu or COVID-19 will not improve one day faster because of them.
  • Taking antibiotics “just in case” helps the bacteria around you learn to resist them, so the drug may fail when you truly need it.
  • Waiting a day or two is often the treatment — not a delay of it.

Most respiratory infections are viral

Most antibiotics prescribed in primary care are aimed at respiratory symptoms, and around 80 percent of those episodes have a viral origin such as influenza, COVID-19 or the common cold, Saber Vivir reported. Molero García adds that even in syndromes with a bacterial component — certain ear infections, sinusitis and acute bronchitis — the real benefit of the drug is more limited than patients and doctors tend to assume.

Current practice favours precision instead: narrow-spectrum penicillins are preferred, because broad-spectrum agents destroy protective as well as harmful bacteria, and short courses of five to seven days are usually sufficient to resolve the infection.

The doctor issues the prescription but asks the patient to wait between 24 and 72 hours before filling it. During that window, the patient simply observes how the illness develops at home.

“Debemos explicar a los pacientes que no prescribir un antibiótico no significa dejarlos sin tratamiento. Significa ofrecer la atención más adecuada, con medidas para aliviar los síntomas, información sobre la evolución esperable y recomendaciones claras sobre cuándo volver a consultar,” Molero García said — translated: “We must explain to patients that not prescribing an antibiotic does not mean leaving them without treatment. It means offering the most appropriate care, with measures to relieve symptoms, information on the expected course and clear recommendations on when to return to the clinic.”

The strategy, as Saber Vivir describes it, suits mild presentations such as ear infections in children over two years old, sinusitis and acute bronchitis in otherwise healthy people.

Rapid tests and the myth of the penicillin allergy

To remove uncertainty from the decision, Spanish family physicians are turning to rapid diagnostic tests: a strep test in the throat, a urine strip or a capillary C-reactive protein check can distinguish a bacterial from a viral infection within minutes, replacing guesswork.

Another target is the allergy label that never was. Between 10 and 15 percent of the population is recorded as penicillin-allergic, yet after proper evaluation about 90 percent of them tolerate the drug perfectly, Saber Vivir reported. Many of those labels trace back to childhood rashes or past digestive upsets; reclassifying them restores access to penicillins, which are safe, inexpensive and effective.

Colonised is not infected

A key clinical distinction the report highlights is the difference between colonisation and infection. A colonised person carries bacteria asymptomatically, without tissue invasion or inflammation — as with bacteria found in the urine of a person who feels well. Treating that finding with antibiotics and no symptoms, so-called asymptomatic bacteriuria, only creates resistance; it is reserved for specific situations such as pregnancy or before surgery.

The numbers behind Spain’s antibiotic habit

Several figures from the Saber Vivir report show the gap between what is prescribed and what the evidence supports:

Figure Value Source
Respiratory infections in primary care that are viral ~80% Saber Vivir / semFYC
Annual deaths from drug-resistant infections in the EU More than 35,000 Saber Vivir
Population labelled penicillin-allergic 10–15% Saber Vivir
Labelled patients confirmed to tolerate penicillin ~90% Saber Vivir
Usual effective course length 5–7 days Saber Vivir / semFYC

When to seek medical advice for worsening symptoms

If symptoms worsen rather than ease after two or three days, patients should fill the prescription or return to the clinic. Anyone with no symptoms should not be treated for bacteria found incidentally, except in pregnancy or before surgery when the report notes the exceptions.

Never take leftover antibiotics from an old box or from a relative, Saber Vivir warns: the drug that works for a throat infection may be useless for a urinary one, and a prescribed course should be completed in full for the five to seven days set — not stopped halfway and not extended without consulting the doctor.

Vaccination against influenza, pneumococcus and whooping cough remains the report's preferred first line of defence, preventing infection rather than treating it.

What this changes for patients this winter

The shift moves the measure of success from the quantity of drugs taken home to the accuracy of the diagnosis. Molero García frames the longer-term stake plainly in the Saber Vivir interview: protecting antibiotics now is what keeps them working for future infections, and a body left to defeat minor viruses on its own builds stronger defences than one habitually rescued by unnecessary shortcuts.

The European Union figure of more than 35,000 resistant-infection deaths a year is the scale of the problem those choices protect against — a public health burden the report ranks as first-order.

References

  • Saber Vivir — interview with Dr. José María Molero García, semFYC Infectious Diseases Working Group, published and updated November 18, 2026.
Photo of author

Health Desk

Health Desk at Archyde.

Bitcoin Pinned Below $65,000 on Dollar Strength, Rate-Hike Bets and Tech Sell-Off

Ottawa, Inuit Leaders Announce $575M Inuit-Governed Child Services Program